Dual and Triple Agonists, Explained

A product page will call something a dual agonist, or a triple agonist, or a tritagonist, and then move straight on to a percentage. What almost none of them explain is what the number counts. It is not potency, and it is not a ranking in which the bigger number wins. It counts receptors: how many different hormone receptors one engineered molecule was designed to switch on. That is the whole idea. The rest of this page is what the count tells you, what it does not, and which of these compounds has published human data underneath the label.

Agonist means it turns a switch on

Cells carry receptors, which are protein switches that respond to one particular signalling molecule. An agonist is anything that fits a given switch and activates it, the way the body's own hormone would. An antagonist fits the same switch and blocks it instead. So a GLP-1 receptor agonist is a molecule shaped closely enough to the gut hormone GLP-1 that the GLP-1 receptor responds to it. Semaglutide is the familiar single-receptor example. That description says nothing about how strong the response is, how long it lasts, or whether any of it turns into something a person would notice. Agonist describes the lock and the key. It is not a claim about the outcome.

Single, dual and triple are a receptor count

Dual and triple simply count targets. Tirzepatide has two. The phase 3 obesity trial that established it describes tirzepatide as a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, and those two receptors, GIP and GLP-1, are what dual refers to. Retatrutide has three. Its phase 2 obesity trial, published in 2023, names them as the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors, and the paper is titled around the phrase triple-hormone-receptor agonist. The count lives in the molecule rather than the marketing. Each of these is a single engineered chain, arranged so that different regions of it are read by different receptors, which is why the technical word for the design is unimolecular: one compound doing what would otherwise take two or three separate agents.^{[1, 2]}

Why anyone added a second and a third target

The honest answer is that it is a research bet, and the trials say as much themselves. The survodutide phase 2 report opens by noting that obesity is a widespread and chronic condition requiring long-term management, and that research into additional targets to improve outcomes remains a priority. That is a stated agenda, not a demonstrated hierarchy. The reasoning underneath it is straightforward enough: different receptors do different jobs, so a molecule that reaches more than one of them may act on more than one part of the problem at once. Whether that reasoning holds for any particular pair or trio is exactly what the trials exist to find out, and for most of these compounds those trials are still running.^[4]

There is one published head-to-head, and it is dual against single

Almost every comparison you will read online is stitched together from separate trials with different participants, different lengths and different placebo groups. That is not a comparison. One published exception exists. SURMOUNT-5 randomly assigned 751 adults with obesity and without type 2 diabetes to the maximum tolerated dose of tirzepatide, the dual agonist, or the maximum tolerated dose of semaglutide, the single agonist, and followed them for 72 weeks. The least-squares mean weight change at week 72 was minus 20.2 percent with tirzepatide and minus 13.7 percent with semaglutide, and the authors conclude that tirzepatide was superior to semaglutide for reduction in body weight and waist circumference at that point. The scope is narrower than the headlines suggested: one trial, one population, two named molecules. It is not evidence that dual beats single as a category, and no published trial has yet put a triple agonist head-to-head against a dual or a single one.^[3]

Not every dual pairs two incretin receptors

The word dual has already drifted away from meaning one thing. Tirzepatide's two targets are both gut hormone receptors. Survodutide's are not: its phase 2 report, published in 2024, describes it as a glucagon and GLP-1 receptor dual agonist, so the second target is glucagon rather than GIP. Amycretin moves outside the family again. Its phase 1b/2a report, published in 2025, calls it a unimolecular GLP-1 and amylin receptor agonist, and amylin is a pancreatic hormone rather than a gut incretin. So dual agonist on its own does not tell you which two receptors are involved, and the two it happens to name change the compound completely. Anyone using the phrase as though it named one settled category has skipped the part that actually matters.^{[4, 5]}

What the extra receptors cost

The product pages tend to stop before this part. In the retatrutide phase 2 trial the most common adverse events were gastrointestinal; the report records them as dose-related, mostly mild to moderate in severity, and partially mitigated by starting lower, alongside dose-dependent increases in heart rate that peaked at 24 weeks and declined afterwards. In the survodutide phase 2 trial, adverse events occurred in 281 of 309 people who received the compound against 58 of 77 on placebo, and only 233 of the 386 people who started finished the 46-week period. In the tirzepatide phase 3 obesity trial, adverse events caused discontinuation in 4.3 to 7.1 percent of the tirzepatide groups against 2.6 percent on placebo. Those three figures are not comparable with one another. They come from different trials with different designs, different escalation schedules and different denominators, and stacking them side by side is a common error in peptide writing. What they do share is a direction. Gastrointestinal effects dominate every one of these programmes, and a substantial number of people leave these trials early.^{[1, 2, 4]}

What a research vial label says about the mechanism

Every compound named on this page is also sold online as a research chemical, and those listings are not a reliable guide to the pharmacology. The enforcement record shows why. In a warning letter dated 31 March 2026, the agency describes a seller offering retatrutide under the house name GLP-1-R peptide and tirzepatide under the house name GLP-2 peptide. GLP-2 is a different hormone with a different receptor, and calling tirzepatide a GLP-2 peptide is simply inaccurate. In a warning letter dated 10 December 2024, the same office quotes another seller's own page describing retatrutide as an experimental tritagonist targeting three hormone receptors, which is closer to the science and still copy written to sell. In both letters the finding was the same, that the products were unapproved new drugs, and these compounds are not approved by the FDA for human use. What that phrase on the label does and does not do is its own subject, and we take it apart at what research use only actually means.^{[6, 7]}

Four questions that decode any of these names

Four questions get you most of the way with a name you have not seen before. First, which receptors, and how many? Dual agonist is an incomplete description until both are named. Second, how far has the evidence actually got? Tirzepatide has phase 3 obesity trials and a head-to-head behind it; retatrutide's largest published obesity trial is phase 2; amycretin's is phase 1b/2a. Third, is the molecule a medicine anywhere, or an investigational compound? Tirzepatide is the active molecule in the prescription drugs Mounjaro and Zepbound, while retatrutide, survodutide and amycretin are investigational, and what is sold online under those names is research chemical stock. Fourth, who was actually in the trial? This work enrolled adults with obesity, in several trials specifically without type 2 diabetes, over periods of 46 to 72 weeks. That is a defined group over a defined stretch of time, and nothing in it speaks to anyone outside it. Our per-compound pages are retatrutide, tirzepatide, survodutide, amycretin and cagrilintide; the head-to-head write-up sits at tirzepatide vs semaglutide, and the wider category is at GLP-1.

References & sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine 2023;389(6):514-526.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine 2022;387(3):205-216.
3. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine 2025;393(1):26-36.
4. le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes and Endocrinology 2024;12(3):162-173.
5. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet 2025;406(10499):149-162.
6. U.S. Food and Drug Administration, Warning Letter to Gram Peptides, MARCS-CMS 721806, issued 31 March 2026.
7. U.S. Food and Drug Administration, Warning Letter to Summit Research Peptides, MARCS-CMS 695607, issued 10 December 2024.